Sabrina Rossi
Biografia
1997 - M.D. (summa cum laude), University of Rome “La Sapienza”. Thesis: Role of the isopeptidase USP2a and Fatty Acid Synthase in prostate cancer. (Thesis advisor: Dr. Loda, Dana-Farber Cancer Institute, Harvard Medical School, Boston).
2011- Ph.D. Program in Experimental Medicine, University of Rome “La Sapienza”. Thesis: “Gastrointestinal stromal tumors: clinico-pathological and molecular characterization of multiple primary sporadic lesions and lesions of small size”. (Thesis advisors: Prof. M Torrisi, Prof. L Ruco).
2017- National Scientific Habilitation as Associate Professor.
Curriculum
Staff Pathologist, Bambino Gesù Children’s Hospital in Rome since November 2018, with 2 areas of interest: neuropathology and skin pathology.
Contract professor at Campus Bio-medico University since November 2019.
Staff pathologist, Regional Hospital of Treviso from January 2003 until November 2018.
PERSONAL STATEMENT: Since November 2018 she has been working as pathologist at the Bambino Gesù Children’s Hospital. Her major clinical and research interest has always been in brain tumors, soft tissue sarcomas and pediatric skin pathology, with a particular emphasis on inherited skin diseases. She has trained as a surgical as well as a molecular pathologist. She focuses on the molecular and immunohistochemical parameters that may aid in the diagnostic process and may predict clinical outcome and/or response to therapy.
PUBBLICAZIONI
Sabrina Rossi is author of more than 100 articles. Below a selection of 10 papers:
Rossi S, et al. Immunofluorescence mapping, electron microscopy and genetics in the diagnosis and sub-classification of inherited epidermolysis bullosa: a single-centre retrospective comparative study of 87 cases with long-term follow-up. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):1007-1016. doi: 10.1111/jdv.17060. Epub 2021 Feb 5. PMID: 33274474.
Pfister SM, et al. A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discov. 2022 Feb;12(2):331-355. doi: 10.1158/2159-8290.CD-21-1094. Epub 2021 Dec 17. PMID: 34921008; PMCID: PMC9401511.
Rossi S, et al. Expanding the spectrum of EWSR1-PATZ1 rearranged CNS tumors: An infantile case with leptomeningeal dissemination. Brain Pathol. 2021 May;31(3):e12934. doi: 10.1111/bpa.12934. Epub 2021 Feb 15. PMID: 33378126; PMCID: PMC8412111.
El Hachem M, et al. A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2620-2629. doi: 10.1111/jdv.16682. Epub 2020 Jul 2. PMID: 32474947; PMCID: PMC7301001.
Fritchie K, et al. The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathol. 2019 Feb;137(2):307-319. doi: 10.1007/s00401-018-1952-6. Epub 2018 Dec 24. PMID: 30584643; PMCID: PMC6513906.
Rossi S, et al. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors. Oncotarget. 2016 May 24;7(21):30109-18. doi: 10.18632/oncotarget.8768. PMID: 27097112; PMCID: PMC5058667.
Brenca M, et al. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol. 2016 Mar;238(4):543-9. doi: 10.1002/path.4677. Epub 2016 Jan 25. PMID: 26606880.
Rossi S, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. Am J Surg Pathol. 2015 Jul;39(7):922-30. doi: 10.1097/PAS.0000000000000418. PMID: 25970686.
Rossi S, et al. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res. 2007 Dec 15;13(24):7322-8. doi: 10.1158/1078-0432.CCR-07-1744. PMID: 18094413.
Rossi S, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003 Aug;1(10):707-15. PMID: 12939396.
